Several drug molecules have been developed in the field of Alzheimer’s disease targeting a wide variety of receptors such as G-protein coupled receptors, kinases/ enzymes, ionotropic channels, hormone receptors, etc., that largely failed during clinical trials [209]. The gene discussed is LPAR2; the disease is Alzheimer disease.